The purpose of this study is to determine the safety and efficacy of 225Ac -labeled PSMA ligand(PSMA-XT) in the treatment of mCRPC
have the ability to understand and sign an approved informed consent form (ICF).
>= 18 years old.
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
have a life expectancy >6 months.
Previous treatment with any of the following within 6 months of enrollment: Strontium-89, Samarium-153, Rhenium-186, Rhenium-188, Radium-223, hemi-body irradiation. Previous PSMA-targeted radioligand therapy is not allowed.
Any systemic anti-cancer therapy (e.g. chemotherapy, immunotherapy or biological therapy within 28 days prior to day of enrollment.
Known hypersensitivity to the components of the study therapy or its analogs.
A superscan as seen in the baseline bone scan.
Xiaorong Sun
Lead sponsor
Shandong Cancer Hospital and Institute
Sponsor institution